| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
McKesson Corporation$835.38
+38.94 (+4.89%)
C 54Pipeline Score Richly Valued Generics · Commercial
Market Cap
106.03 B
EPS
34.92
P/E Ratio
24.9 $
Value Trade
580.28 M
SEC Financials
Q1 2026Dilution Risk
Revenue
403.43 B
Operating CF
6.16 B
Total Assets
82.32 B
Total Liabilities
82.32 B
Equity
-2.17 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
4.07 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
450.33 K
52 Week Range
637 - 999
% held by Insiders
0.05 %
% held by Institutions
96.22 %
Enterprise Value
112.80 B
Total Shares
120.19 M
Short %
3.52 %
Float Shares
120.19 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C54
Pipeline Score $4.7B
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 81%
Large Pharma (rank 174 of 912)
Percentile RankMcKesson Corporation carries a moderate pipeline score (54/100), with $9.4B risk-adjusted pipeline value, led by Text messages, Usual care in Type 2 Diabetes Mellitus (Phase 2), across $101B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Text messages, Usual care Unknown | Type 2 Diabetes Mellitus | Phase 2 | NCT01569243 | 45% | $9.4B | COMPLETED | 126 | - | - | Oct 1, 2013 | - | Sep 1, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MCK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MCK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-MCK
Jul 13, 2026▲ +4.9%today
McKesson Releases Fiscal Year 2026 Impact Report
McKesson has released its Fiscal Year 2026 Impact Report, showcasing the company's initiatives in transforming its purpose into actionable steps within the healthcare sector. The report emphasizes McKesson's commitment to improving healthcare outcomes and corporate responsibility. This release reflects the company's ongoing efforts to make a positive impact in the industry.
Read more →-MCK
Jun 24, 2026McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
McKesson Corporation has announced the date for its earnings release for the first quarter of fiscal 2027. The announcement provides investors with important information regarding the company's financial performance. Further details regarding the earnings report will likely follow closer to the release date.
Read more →-MCK
Jun 23, 2026McKesson ideaShare 2026 Fuels Momentum for Independent Pharmacies
The article discusses the McKesson ideaShare 2026 event, which aims to support independent pharmacies. It highlights the importance of collaboration and innovation in enhancing pharmacy operations. However, specific details about the event's impact or outcomes are not provided.
Read more →-MCK
Jun 2, 2026McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
McKesson has finalized a strategic investment with Apollo Funds, acquiring a minority interest in its Medical-Surgical Solutions segment. This move is part of McKesson's strategy to enhance its offerings in the medical-surgical market. The investment is expected to strengthen McKesson's position in the healthcare supply chain.
Read more →-MCK
May 7, 2026McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets
McKesson has reported its financial results for the fourth quarter and full year of fiscal 2026. The company also provided guidance for fiscal 2027 and reaffirmed its long-term financial growth targets. The report indicates a stable outlook for the company moving forward.
Read more →-MCK
Apr 22, 2026McKesson Corporation Declares Quarterly Dividend
McKesson Corporation's Board of Directors has declared a quarterly dividend of 82 cents per share, payable on July 1, 2026. Shareholders of record as of June 1, 2026, will receive this dividend. This announcement highlights McKesson's ongoing commitment to shareholder value and financial health.
Read more →-MCK
Apr 20, 2026McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions
McKesson has signed an agreement with Apollo Funds to secure a strategic minority interest in its Medical-Surgical Solutions division. This partnership aims to enhance McKesson's capabilities in the medical-surgical market. Further details about the financial implications or strategic goals of this agreement were not disclosed in the announcement.
Read more →-MCK
Mar 6, 2026MCKESSON CORPORATION ANNOUNCES FOURTH QUARTER FISCAL 2026
McKesson Corporation has announced that it will release its fourth quarter fiscal 2026 financial results after the market closes on May 7, 2026. CEO Brian Tyler and CFO Britt Vitalone will host a live webcast to discuss these results. Vitalone is also scheduled to participate in several upcoming healthcare conferences, indicating McKesson's active involvement in the industry. Furthermore, the company has reaffirmed its full-year outlook for fiscal 2026, reflecting confidence in its financial performance.
Read more →-MCK
Mar 5, 2026McKesson Announces Planned CFO Transition
McKesson Corporation announced the retirement of CFO Britt Vitalone after 20 years, with Kenny Cheung set to succeed him on May 29, 2026. Vitalone will remain as a strategic advisor during the transition. The company continues to perform well, reporting record revenue and profits, signaling strong momentum in its business operations.
Read more →-MCK
Mar 5, 2026McKesson Announces Planned CFO Transition Britt Vitalone announces retirement, Kenny Cheung named as successor
McKesson Corporation announced the retirement of CFO Britt Vitalone after a commendable 20-year tenure, with Kenny Cheung set to succeed him effective May 29, 2026. Vitalone will remain with the company as a strategic advisor, supporting a smooth leadership transition and the planned separation of McKesson's Medical Surgical Solutions segment. The leadership change occurs as McKesson continues to achieve strong financial performance, reporting record revenue and operating profits in its recent earnings announcement.
Read more →-MCK
Feb 5, 2026▲ +16.5%on this news
McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance
McKesson Corporation has announced its fiscal 2026 third quarter financial results, showcasing a strong performance. The company has also raised its full-year adjusted EPS guidance, indicating confidence in its financial trajectory. A live webcast of the earnings conference call will be held for investors to discuss these results.
Read more →-MCK
Feb 4, 2026McKESSON CORPORATION REPORTS FISCAL 2026
McKesson Corporation reported strong financial results for the third quarter of fiscal 2026, with quarterly revenues of $106.2 billion, representing an 11% increase. The company raised its adjusted earnings per diluted share guidance to between $38.80 and $39.20, indicating a projected growth of 17% to 19% compared to the previous year. Key drivers of revenue growth included increased prescription volumes from retail clients and performance improvements in its oncology and multispecialty platforms. Additionally, McKesson successfully divested its Norwegian retail operations, reinforcing its strategic focus on sustainable growth and core distribution businesses.
Read more →-MCK
Jan 29, 2026McKesson Corporation Declares Quarterly Dividend - January 28, 2026
McKesson Corporation's Board of Directors has declared a quarterly dividend of 82 cents per share, which will be payable on April 1, 2026, to shareholders recorded by March 2, 2026. This decision highlights the company's ongoing commitment to providing value to its investors.
Read more →-MCK
Sep 23, 2025▲ +6.4%on this news
losses not covered by insurance or indemnification we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws we from time to time record significant charges from impairment to g
McKesson Corporation hosted its 2025 Investor Day to share strategic growth priorities and long-term financial targets. The company detailed its focus on enhancing North American Pharmaceutical distribution and expanding its services in oncology and biopharma. McKesson raised its Fiscal 2026 Adjusted Earnings guidance and introduced higher long-term growth targets for its adjusted earnings. However, the firm also acknowledged significant risks involving legal disputes and compliance with healthcare regulations.
Read more →-MCK
Sep 18, 2025SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION McKesson Corporation (the Company, we, or our ) is furnishing to investors supplemental historical financial information by new reportable segment for our quarterly r
McKesson Corporation is providing supplemental historical financial information segmented by new reportable categories for its quarterly and annual results. This change follows a reassessment of its organizational structure and aims to enhance transparency for investors regarding the impact of these segment changes. Starting in the second quarter of fiscal 2026, McKesson will report financial results in four segments: North American Pharmaceutical, Oncology Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The adjustments are designed to better allocate resources and assess performance without affecting previous financial statements.
Read more →-MCK
May 20, 2025McKESSON CORPORATION 4.650% Notes due 2030 4.950% Notes due 2032 5.250% Notes due 2035 _________________________ Underwriting Agreement
McKesson Corporation is proposing to issue three series of notes totaling $2 billion, including 4.650% notes due in 2030, 4.950% notes due in 2032, and 5.250% notes due in 2035. The issuance is facilitated by major underwriters, including Barclays and J.P. Morgan. The notes will be issued under a base indenture and a prospectus has been prepared and filed with the Securities and Exchange Commission. This move aims to expand McKesson's financial resources and offer investment opportunities.
Read more →-MCK
May 8, 2025McKESSON REPORTS FISCAL 2025 FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES FISCAL 2026 GUIDANCE ANNOUNCES INTENT TO SEPARATE MEDICAL-SURGICAL
McKesson Corporation reported strong financial results for the fourth quarter and fiscal year ended March 31, 2025, with revenues of $90.8 billion, reflecting a 19% increase. The company also announced an intention to separate its Medical-Surgical Solutions segment into an independent entity, aiming to enhance operational focus and stakeholder value. For fiscal 2026, McKesson provided earnings guidance predicting 11% to 14% growth, reaffirming its long-term earnings targets. The separation is designed to allow both companies to concentrate on higher growth opportunities within their markets.
Read more →-MCK
Feb 5, 2025McKESSON CORPORATION REPORTS FISCAL 2025
McKesson Corporation reported strong third quarter results for fiscal 2025, with revenues reaching $95.3 billion, marking an 18% increase year-over-year. The company raised its full-year Adjusted Earnings per Diluted Share guidance to a range of $32.55 to $32.95, indicating robust operational performance. A significant milestone includes the acquisition of an 80% interest in PRISM Vision Holdings, enhancing its position in community practice management. However, despite the overall positives, net income showed a decline of 8% during the first nine months of the fiscal year.
Read more →-MCK
Sep 5, 2024▼ -9.9%on this news
Execution Version McKESSON CORPORATION 4.250% Notes due 2029 _________________________ Underwriting Agreement
McKesson Corporation has announced an agreement to issue $500 million in 4.250% Notes due 2029 under the supervision of established underwriters including Citigroup, HSBC, and U.S. Bancorp. The issuance follows the compliance with the Securities Act as confirmed by the company's registration statement. The notes will be made available in book-entry form and are part of a broader strategy to facilitate capital generation and financial fluidity for the company.
Read more →-MCK
Aug 26, 2024Cautionary Statements Except for historical information, statements in this press release regarding McKesson's proposed acquisition and related arrangements constitute "forward-looking statements" within the meaning of S
McKesson Corporation has announced a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC, for approximately $2.49 billion. This strategic acquisition aims to enhance McKesson's oncology platform while integrating Florida Cancer Specialists Research Institute into The US Oncology Network. The partnership is expected to improve community-based cancer care and patient outcomes. However, the completion of the transaction is contingent on customary closing conditions, including regulatory approvals, and carries inherent uncertainties.
Read more →-MCK
Aug 7, 2024McKESSON CORPORATION REPORTS FISCAL 2025 FIRST QUARTER RESULTS First Quarter Highlights Consolidated revenues of $79.3 billion increased 6%. Earnings per diluted share of $7.00 decreased $0.02. Adjusted Earnings per Dilu
McKesson Corporation reported its fiscal 2025 first quarter results with consolidated revenues of $79.3 billion, reflecting a 6% increase year-over-year. While earnings per diluted share saw a slight decrease to $7.00, adjusted earnings per diluted share increased by 8% to $7.88. The company also announced a 15% dividend increase and raised its adjusted earnings guidance for the fiscal year, indicating a positive outlook. However, challenges were noted in the Prescription Technology Solutions segment which affected overall revenue contributions.
Read more →-MCK
Jun 3, 2024Rachel Rodriguez, 469-260-0556 (Investors) Rachel.Rodriguez McKesson.com Media Relations MediaRel ations McKesson.com
McKesson Corporation has elected Dr. Deborah Dunsire as a new director on its Board, effective June 3, 2024. Dr. Dunsire is recognized for her extensive experience in the healthcare industry, including leadership roles at various biopharmaceutical companies. She succeeds Linda Mantia and Susan Salka, who will not be standing for re-election. This move aims to strengthen McKesson's governance and expertise in advancing health outcomes.
Read more →-MCK
May 7, 2024Document McKESSON CORPORATION REPORTS FISCAL 2024 FOURTH QUARTER AND FULL YEAR RESULTS Fourth Quarter Highlights Consolidated revenues of $76.4 billion increased by 11%. Earnings per diluted share from continuing operati
McKesson Corporation announced its fiscal 2024 fourth quarter and full year results, showcasing a revenue increase of 11% in the fourth quarter. However, adjusted earnings per diluted share for the quarter decreased by 14%, reflecting challenges amidst growth. Despite these setbacks, the company anticipates a robust fiscal 2025, projecting adjusted earnings per share growth of 14% to 17%. McKesson continues to expand its healthcare initiatives, focusing on equity and advanced oncology services, while managing increased corporate expenses.
Read more →-MCK
Feb 7, 2024Document McKESSON CORPORATION REPORTS FISCAL 2024 THIRD QUARTER RESULTS AND RAISES FULL YEAR GUIDANCE Third Quarter Highlights Consolidated revenues of $80.9 billion increased 15%. Earnings per diluted share from continu
McKesson Corporation reported strong financial performance for the third quarter of fiscal 2024, with consolidated revenues rising by 15% to $80.9 billion. Despite a decrease in earnings per diluted share from continuing operations, adjusted earnings improved by 12%. The company has raised its guidance for adjusted earnings per diluted share, reflecting positive operational momentum. However, concerns were noted regarding significant bad debt provisions linked to external factors such as the Rite Aid bankruptcy.
Read more →-MCK
Jan 9, 2024These risk factors include, but are not limited to we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids we might experienc
McKesson Corporation presented at the 42nd Annual J.P. Morgan Healthcare Conference, highlighting its recent acquisition of Compile, a healthcare data platform. The company also announced the election of Kevin Ozan to its Board of Directors. The acquisition is expected to enhance McKesson's ability to aggregate healthcare data, supporting its growth initiatives. However, the company acknowledged several risk factors, including ongoing legal disputes and potential financial losses related to its operations, particularly concerning opioids.
Read more →-MCK
Nov 1, 2023Document McKESSON CORPORATION REPORTS FISCAL 2024 SECOND QUARTER RESULTS AND RAISES FULL YEAR GUIDANCE Second Quarter Highlights Total revenues of $77.2 billion increased 10%. Earnings per diluted share from continuing o
McKesson Corporation reported a 10% increase in total revenues for the second quarter of fiscal 2024, totaling $77.2 billion. Adjusted earnings per diluted share were up by 3%, prompting the company to raise its full-year guidance to a range of $26.80 to $27.40. Despite revenue growth, earnings per share from continuing operations decreased due to a significant provision for bad debts linked to Rite Aid’s bankruptcy. The performance reflects strong growth in its U.S. Pharmaceutical segment, which is expected to continue in the coming months.
Read more →-MCK
Aug 2, 2023Document McKESSON CORPORATION REPORTS FISCAL 2024 FIRST QUARTER RESULTS First Quarter Highlights Total revenues of $74.5 billion increased 11%. Earnings per diluted share from continuing operations of $7.02 increased $1.
McKesson Corporation reported robust financial results for the first quarter of fiscal 2024, with total revenues reaching $74.5 billion, a growth of 11% year-over-year. Earnings per diluted share from continuing operations rose to $7.02, marking a significant increase of $1.77. The company also announced a $6.0 billion increase to its share repurchase program and a 15% hike in quarterly dividends. However, it faced challenges in its international segment, with a notable revenue decline attributed to recent divestitures.
Read more →-MCK
Jun 7, 2023Execution Version McKESSON CORPORATION 4.900% Notes due 2028 5.100% Notes due 2033 Underwriting Agreement
McKesson Corporation has announced an underwriting agreement to issue $1 billion in senior notes, structured into two tranches: $400 million of 4.900% Notes due 2028 and $600 million of 5.100% Notes due 2033. The offering is backed by a registered statement filed with the SEC, confirming the company's adherence to regulatory requirements. The transaction will be managed by BofA Securities, Goldman Sachs, and J.P. Morgan as representatives of the underwriters.
Read more →-MCK
Jun 7, 2023McKesson Corporation Commences Tender Offer for Any and All 3.796% Notes Due 2024
McKesson Corporation has initiated a tender offer to purchase any and all outstanding 3.796% Notes due 2024 for cash. The tender offer will expire on June 13, 2023, and participation requires valid tendering of the notes prior to the expiration or through guaranteed delivery procedures. Holders of the notes will also receive accrued interest up to the payment date. The tender offer is subject to certain conditions, including the successful completion of a new offering of senior notes to fund the repurchase.
Read more →-MCK
May 8, 2023Document McKESSON CORPORATION REPORTS FISCAL 2023 FOURTH-QUARTER AND FULL-YEAR RESULTS AND RAISES LONG-TERM SEGMENT GROWTH TARGETS Fourth-Quarter Highlights Total revenues of $68.9 billion increased 4%. Earnings per dilu
McKesson Corporation reported strong fiscal results for Q4 2023 and the full year, with total revenues rising to $68.9 billion for Q4, an increase of 4%, and $276.7 billion for the full year, reflecting a 5% growth. Earnings per diluted share increased significantly, with a notable rise of $3.23 in Q4. Despite challenges in the International segment and a decline in the Medical-Surgical Solutions segment revenues, the company remains optimistic about its growth prospects, raising long-term growth targets. Cash flow from operations and investments in capital expenditures reflected robust financial health.
Read more →-MCK
Feb 13, 2023McKESSON CORPORATION 5.250% Notes due 2026 Underwriting Agreement
McKesson Corporation has entered into an underwriting agreement to issue $500 million of 5.250% Notes due in 2026. The underwriters for this issuance include BNP Paribas Securities Corp. and Wells Fargo Securities, LLC. The Notes will be issued under a Base Indenture with a trustee and are compliant with the Securities Act of 1933, affirming that there are no pending objections from the SEC. This agreement indicates a strong market position and solid investor confidence in McKesson's financial instruments.
Read more →-MCK
Feb 1, 2023Document McKESSON CORPORATION REPORTS FISCAL 2023 THIRD-QUARTER RESULTS AND RAISES FULL-YEAR GUIDANCE Third-Quarter Highlights Total revenues of $70.5 billion increased 3%. Earnings per diluted share from continuing oper
McKesson Corporation reported strong fiscal 2023 third-quarter results, with total revenues reaching $70.5 billion, reflecting a 3% increase from the previous year. Notably, adjusted earnings per diluted share rose by 12%, prompting the company to raise its full-year guidance for adjusted earnings to between $25.75 and $26.15. While growth in the U.S. Pharmaceutical segment and oncology services drove performance, certain segments experienced revenue declines, particularly in Medical-Surgical Solutions due to reduced demand for COVID-19 related products. Overall, McKesson's operational strengths and strategic initiatives position it well for continued growth.
Read more →-MCK
Nov 1, 2022McKESSON CORPORATION REPORTS FISCAL 2023 SECOND-QUARTER RESULTS AND RAISES FULL-YEAR GUIDANCE Second-Quarter Highlights Total revenues of $70.2 billion increased 5%. Earnings per diluted share from continuing operations
McKESSON CORPORATION REPORTS FISCAL 2023 SECOND-QUARTER RESULTS AND RAISES FULL-YEAR GUIDANCE Second-Quarter Highlights Total revenues of $70.2 billion increased 5%. Earnings per diluted share from continuing operations of $6.46 increased $4.75. Adjusted Earnings per Diluted
Read more →-MCK
Sep 13, 2022About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, phar
EX-99.1 2 ex991-502boardofdirectorap.htm EX-99.1 BOARD OF DIRECTOR APPOINTMENTS (9-13-22) Document Press Release Exhibit 99.1 McKesson Names LeAnn B. Smith as Next Chief Human Resources Officer Tracy L. Faber to Retire After More Than a Decade at the Company IRVING, TX, September
Read more →-MCK
Aug 3, 2022McKESSON CORPORATION REPORTS FISCAL 2023 FIRST-QUARTER RESULTS First-Quarter Highlights Total revenues of $67.2 billion increased 7%. Earnings per diluted share from continuing operations of $5.25 increased $2.16. Adjust
McKESSON CORPORATION REPORTS FISCAL 2023 FIRST-QUARTER RESULTS First-Quarter Highlights Total revenues of $67.2 billion increased 7%. Earnings per diluted share from continuing operations of $5.25 increased $2.16. Adjusted Earnings per Diluted Share of $5.83 increased 5%. Ad
Read more →-MCK
May 5, 2022McKESSON REPORTS FISCAL 2022 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-Quarter Highlights Total revenues of $66.1 billion increased 12%. Earnings per diluted share from continuing operations of $2.48 decreased $1.67. A
McKESSON REPORTS FISCAL 2022 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-Quarter Highlights Total revenues of $66.1 billion increased 12%. Earnings per diluted share from continuing operations of $2.48 decreased $1.67. Adjusted Earnings per Diluted Share of $5.83 increased 15
Read more →-MCK
Apr 1, 2022McKesson's Board of Directors Elects W. Roy Dunbar as New Director
EX-99.1 2 ex991-502boardofdirectorap.htm EX-99.1 MCK_8-K_5.02_DIRECTOR APPOINTMENT - ROY DUNBAR Document Press Release Exhibit 99.1 McKesson's Board of Directors Elects W. Roy Dunbar as New Director IRVING, Texas, April. 1, 2022 - (NYSE MCK) announced today that the McKesson boar
Read more →-MCK
Feb 25, 2022List of states and territories that have agreed to the opioids-related Settlement Alaska Missouri American Samoa Montana Arizona N. Mariana Islands Arkansas Nebraska California Nevada Colorado New Hampshire Connecticut N
Alaska Missouri American Samoa Montana Arizona N. Mariana Islands Arkansas Nebraska California Nevada Colorado New Hampshire Connecticut New Jersey Delaware New Mexico District of Columbia New York Florida North Carolina Georgia North Dakota Guam Ohio Hawaii Oregon Idaho Pennsylv
Read more →-MCK
Jan 18, 2022McKesson's Board of Directors Elects James H. Hinton and Kathleen Wilson-Thompson as New Directors
EX-99.1 2 ex991-502boardofdirectorap.htm EX-99.1 BOARD OF DIRECTORS APPOINTMENTS 1-13-22 Document Press Release Exhibit 99.1 McKesson's Board of Directors Elects James H. Hinton and Kathleen Wilson-Thompson as New Directors IRVING, Texas, Jan. 18, 2022 - McKesson Corporation (NYS
Read more →-MCK
Jan 13, 2022McKESSON REPORTS FISCAL 2022 THIRD-QUARTER RESULTS Third-Quarter Highlights, Year-over-Year Total revenues of $68.6 billion increased 10%. Loss per diluted share from continuing operations of ($0.04), an increase of $38.
McKESSON REPORTS FISCAL 2022 THIRD-QUARTER RESULTS Third-Quarter Highlights, Year-over-Year Total revenues of $68.6 billion increased 10%. Loss per diluted share from continuing operations of ($0.04), an increase of $38.99 due to a prior year pre-tax charge of $8.1 billion rel
Read more →-MCK
Nov 1, 2021McKESSON REPORTS FISCAL 2022 SECOND-QUARTER RESULTS Second-Quarter Highlights, Year-over-Year Total revenues of $66.6 billion increased 9% Earnings per diluted share from continuing operations of $1.71 decreased $1.83 Ad
McKESSON REPORTS FISCAL 2022 SECOND-QUARTER RESULTS Second-Quarter Highlights, Year-over-Year Total revenues of $66.6 billion increased 9% Earnings per diluted share from continuing operations of $1.71 decreased $1.83 Adjusted Earnings per Diluted Share of $6.15 increased 28%
Read more →-MCK
Sep 7, 2021McKesson's Board of Directors Elects Dr. Richard H. Carmona as New Independent Director
EX-99.1 2 ex991-502boardofdirectorsa.htm BOARD OF DIRECTORS APPOINTS RICHARD CARMONA Document Press Release Exhibit 99.1 McKesson's Board of Directors Elects Dr. Richard H. Carmona as New Independent Director IRVING, Texas, Sept. 7, 2021 - McKesson Corporation (NYSE MCK) announce
Read more →-MCK
Aug 9, 2021McKESSON CORPORATION 1.300% Notes due 2026 Underwriting Agreement
McKESSON CORPORATION 1.300% Notes due 2026 Underwriting Agreement Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 United States of America Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 United States of America As Represen
Read more →-MCK
Aug 4, 2021McKESSON REPORTS FISCAL 2022 FIRST-QUARTER RESULTS First-Quarter Highlights, Year-over-Year Total revenues of $62.7 billion increased 13% Earnings per diluted share from continuing operations of $3.09 increased 14% Adjus
McKESSON REPORTS FISCAL 2022 FIRST-QUARTER RESULTS First-Quarter Highlights, Year-over-Year Total revenues of $62.7 billion increased 13% Earnings per diluted share from continuing operations of $3.09 increased 14% Adjusted Earnings per diluted share of $5.56 increased 101%
Read more →-MCK
Jul 2, 2021Registered Certified Mail Regular Mail or Courier In Person by Hand Only Elavon Financial Services DAC 125 Old Broad Street, Fifth Floor London, EC2N 1AR United Kingdom Elavon Financial Services DAC 125 Old Broad Street,
Notice of Full Redemption McKesson Corporation 0.625% Notes due August 17, 2021 (ISIN NO. XS1567173809 COMMON CODE 156717380)* Reference is made to the Indenture, dated as of December 4, 2012 (the "Base Indenture"), by and between McKesson Corporation, a Delaware corporation
Read more →-MCK
May 6, 2021McKESSON REPORTS FISCAL 2021 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-Quarter and Full-Year Highlights Fourth-quarter total revenues of $59.1 billion increased 1% Full-year total revenues of $238.2 billion increased 3
McKESSON REPORTS FISCAL 2021 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-Quarter and Full-Year Highlights Fourth-quarter total revenues of $59.1 billion increased 1% Full-year total revenues of $238.2 billion increased 3% Fourth-quarter earnings per diluted share from continu
Read more →-MCK
Apr 19, 2021NOTICE OF DIRECTOR DECISION TO NOT STAND FOR RE-ELECTION Document Press Release McKesson Announces N. Anthony Coles, M.D. will not stand for re-election to McKesson Board of Directors
McKesson Announces N. Anthony Coles, M.D. will not stand for re-election to McKesson Board of Directors IRVING, Texas, April 19, 2021 - McKesson Corporation today announced that N. Anthony Coles, M.D., informed the company he will not stand for re-election to the McKesson Board
Read more →-MCK
Feb 2, 2021McKESSON REPORTS FISCAL 2021 THIRD-QUARTER RESULTS Third-Quarter Highlights, Year-over-Year Total revenues of $62.6 billion, reflecting 6% growth. McKesson recorded a pre-tax charge of $8.1 billion related to opioid liti
McKESSON REPORTS FISCAL 2021 THIRD-QUARTER RESULTS Third-Quarter Highlights, Year-over-Year Total revenues of $62.6 billion, reflecting 6% growth. McKesson recorded a pre-tax charge of $8.1 billion related to opioid litigation, resulting in third-quarter Loss per diluted share
Read more →-MCK
Nov 30, 2020EXECUTION VERSION McKESSON CORPORATION 0.900% Notes due 2025 Underwriting Agreement
EXECUTION VERSION McKESSON CORPORATION 0.900% Notes due 2025 Underwriting Agreement November 30, 2020 BofA Securities, Inc. One Bryant Park New York, New York 10036 United States of America HSBC Securities (USA) Inc. 452 Fifth Avenue New York, New York 10018 United St
Read more →-MCK
Nov 1, 2020McKESSON REPORTS FISCAL 2021 SECOND-QUARTER RESULTS Second-Quarter Highlights, Year-over-Year Total revenues of $60.8 billion, reflecting 6% g rowth. Earnings per diluted share increa sed by $7.53 to $3.54. Adjusted Earn
McKESSON REPORTS FISCAL 2021 SECOND-QUARTER RESULTS Second-Quarter Highlights, Year-over-Year Total revenues of $60.8 billion, reflecting 6% growth. Earnings per diluted share increased by $7.53 to $3.54. Adjusted Earnings per diluted share of $4.80, an increase of 33%. Comp
Read more →-MCK
Oct 19, 2020BOARD OF DIRECTORS APPOINTS LINDA MANTIA Document Press Release McKesson's Board of Directors Appoints Linda Mantia as New Independent Director
EX-99 2 ex991-50210x19x20board.htm EX-99.1 BOARD OF DIRECTORS APPOINTS LINDA MANTIA Document Press Release McKesson's Board of Directors Appoints Linda Mantia as New Independent Director IRVING, Texas - Oct. 19, 2020 - McKesson Corporation (NYSE MCK) today announced that the McKe
Read more →-MCK
Sep 22, 2020SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION McKesson Corporation (the "Company," "we," or "our") is furnishing to investors supplemental historical financial information by new reportable segment for our quarte
SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION McKesson Corporation (the "Company," "we," or "our") is furnishing to investors supplemental historical financial information by new reportable segment for our quarterly results of fiscal 2020 and first quarter of fiscal 2021
Read more →-MCK
Aug 3, 2020McKESSON REPORTS FISCAL 2021 FIRST-QUARTER RESULTS First-Quarter Highlights, Year-over-Year Total revenue s of $55.7 billion, flat year-over-year. Earnings per diluted share increased 20% to $2.72. Adjusted Earnings per
McKESSON REPORTS FISCAL 2021 FIRST-QUARTER RESULTS First-Quarter Highlights, Year-over-Year Total revenues of $55.7 billion, flat year-over-year. Earnings per diluted share increased 20% to $2.72. Adjusted Earnings per diluted share decreased 16% to $2.77. Board of Directors
Read more →-MCK
Jul 1, 20207-1-2020 Exhibit McKesson Realigns Organizational Structure to Better Serve Customers and Patients While Optimizing Growth
EX-99.1 2 exhibit991pressrelease.htm EXHIBIT 99.1 PRESS RELEASE 7-1-2020 Exhibit McKesson Realigns Organizational Structure to Better Serve Customers and Patients While Optimizing Growth IRVING, Texas, July 1, 2020 - McKesson Corporation (NYSE:MCK) today announces changes to its
Read more →-MCK
May 20, 2020McKESSON REPORTS FISCAL 2020 FOURTH -QUARTER AND FULL-YEAR RESULTS Fourth -Quarter Highlights, Year-over-Year: Total revenues of $58.5 billion , reflecting 12% growth. Earnings per diluted share increased by $9.99 to $5.
McKESSON REPORTS FISCAL 2020 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-Quarter Highlights, Year-over-Year: Full-Year Highlights: Fiscal 2021 Outlook: IRVING, Texas, May 20, 2020 - McKesson Corporation (NYSE:MCK) today reported results for the fourth quarter and fiscal year
Read more →-MCK
Mar 17, 2020EX-99.1 2 exhibit991pressrelease.htm EXHIBIT 99.1 Exhibit McKESSON UPDATES FISCAL 2020 GUIDANCE FOLLOWING COMPLETION OF CHANGE HEALTHCARE SPLIT-OFF IRVING, Texas, March 17, 2020 -
EX-99.1 2 exhibit991pressrelease.htm EXHIBIT 99.1 Exhibit McKESSON UPDATES FISCAL 2020 GUIDANCE FOLLOWING COMPLETION OF CHANGE HEALTHCARE SPLIT-OFF IRVING, Texas, March 17, 2020 - McKesson Corporation (NYSE:MCK) today announced it is updating its adjusted earnings outlook for the
Read more →-MCK
Mar 10, 2020McKESSON
McKESSON ANNOUNCES PRELIMINARY RESULTS OF EXCHANGE OFFER IRVING, TEXAS March 10, 2020 McKesson Corporation (NYSE:MCK) today announced that its previously announced offer to stockholders to exchange their shares of McKesson common stock on a per-share-basis for 11.4086 shares of
Read more →-MCK
Mar 5, 2020McKESSON SETS FINAL EXCHANGE RATIO OF 11.4086
McKESSON SETS FINAL EXCHANGE RATIO OF 11.4086 FOR EXCHANGE OFFER IRVING, TEXAS March 5, 2020 McKesson Corporation (NYSE:MCK) today announced the final exchange ratio of 11.4086-for-one in connection with its previously announced offer to its stockholders to exchange their shares
Read more →-MCK
Feb 10, 2020McKesson Launches Exchange Offer to Split-Off its Interest in Change Healthcare
McKesson Launches Exchange Offer to Split-Off its Interest in Change Healthcare February 10, 2020 Irving, Texas, February 10, 2020 McKesson Corporation (NYSE:MCK) today announced the commencement of an exchange offer for the split-off of its wholly-owned subsidiary, PF2 SpinCo,
Read more →-MCK
Jan 13, 20201-13-20 Exhibit McKESSON TO PRESENT AT THE 38 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EX-99.1 2 ex991pressrelease1-13x.htm EXHIBIT 99.1 PRESS RELEASE 1-13-20 Exhibit McKESSON TO PRESENT AT THE 38 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE: WILL PROVIDE COMPANY OVERVIEW AND REVIEW UPDATED FINANCIAL OUTLOOK IRVING, Texas, January 13, 2020 - McKesson Corporation (NY
Read more →-MCK
Dec 18, 2019McKESSON REAFFIRMS FISCAL 2020
McKESSON REAFFIRMS FISCAL 2020 GUIDANCE IRVING, Texas, December 18, 2019 McKesson Corporation (NYSE:MCK) today reaffirmed its Adjusted Earnings per diluted share guidance of $14.00 to $14.60 for the fiscal year ending March 31, 2020. McKesson is hosting a sell-side analyst meet
Read more →-MCK
Dec 12, 2019McKesson Selected by Department of Veterans Affairs as Prime Pharmaceutical Provider Pharmaceutical distributor continues long-standing relationship with VA Healthcare System
McKesson Selected by Department of Veterans Affairs as Prime Pharmaceutical Provider Pharmaceutical distributor continues long-standing relationship with VA Healthcare System IRVING, Texas, Dec. 12, 2019 McKesson Corporation (NYSE: MCK) announced today that it has been selected
Read more →-MCK
Oct 30, 2019McKESSON REPORTS FISCAL 2020 SECOND-QUARTER RESULTS Total revenues of $57.6 billion, reflecting 9% growth. Loss per diluted share of $(3.99) and Adjusted Earnings per diluted share of $3.60. Reaffirmed fiscal 2020 Adjust
McKESSON REPORTS FISCAL 2020 SECOND-QUARTER RESULTS IRVING, Texas, October 30, 2019 McKesson Corporation (NYSE:MCK) today reported results for the second quarter ended September 30, 2019. Fiscal 2020 Second-Quarter and Year-to-Date Result Summary McKesson s second-quarter resu
Read more →-MCK
Oct 18, 2019McKesson s Board of Directors Appoints Maria Martinez as New Independent Director
McKesson s Board of Directors Appoints Maria Martinez as New Independent Director IRVING, Texas Oct. 18, 2019 McKesson Corporation (NYSE: MCK) today announced that its board of directors appointed Maria Martinez as a new independent director, effective Oct. 18, 2019. With the ap
Read more →-MCK
Jul 31, 2019McKESSON REPORTS FISCAL 2020 FIRST-QUARTER RESULTS First-quarter fiscal 2020 revenues of $55.7 billion, an increase of 6%. First-quarter GAAP earnings per diluted share from continuing operations of $2.27, up 429% year o
McKESSON REPORTS FISCAL 2020 FIRST-QUARTER RESULTS IRVING, Texas, July 31, 2019 McKesson Corporation (NYSE:MCK) today reported that revenues for the first quarter ended June 30, 2019, were $55.7 billion compared to $52.6 billion a year ago, an increase of 6% on a reported basis
Read more →-MCK
Jun 17, 2019McKesson s Board of Directors Elects Dr. Ken Washington as New Independent Director IRVING, TX
McKesson s Board of Directors Elects Dr. Ken Washington as New Independent Director IRVING, TX June 17, 2019 McKesson Corporation (NYSE: MCK) today announced that its board of directors elected Dr. Ken Washington as a new independent director, effective July 1, 2019. With the el
Read more →-MCK
May 8, 2019McKESSON REPORTS FISCAL 2019 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-quarter fiscal 2019 revenues of $52.4 billion and full-year fiscal 2019 revenues of $214.3 billion, a full-year increase of 3%. Fourth-quarter GAAP
McKESSON REPORTS FISCAL 2019 FOURTH-QUARTER AND FULL-YEAR RESULTS IRVING, Texas, May 8, 2019 McKesson Corporation (NYSE:MCK) today reported that revenues for the fourth quarter ended March 31, 2019, were $52.4 billion compared to $51.6 billion a year ago, an increase of 2% on a
Read more →-MCK
May 8, 2019CORRECTING and REPLACING McKesson Reports Fourth Quarter and Full Year 2019 Results CORRECTION by McKesson Corporation.
CORRECTING and REPLACING McKesson Reports Fourth Quarter and Full Year 2019 Results CORRECTION by McKesson Corporation. IRVING, Texas, May 8, 2019 - (BUSINESS WIRE) - Schedule 5, Condensed Consolidated Statements of Cash Flows is corrected to include the line Gain from Sale of
Read more →-MCK
Apr 26, 2019Investors and Financial Media: Holly Weiss | 972-969-9174 | Holly.Weiss@McKesson.com General and Business Media: Kristin Chasen | 415-983-8974 | Kristin.Chasen@McKesson.com McKesson Appoints Tracy F
Investors and Financial Media: Holly Weiss | 972-969-9174 | Holly.Weiss@McKesson.com General and Business Media: Kristin Chasen | 415-983-8974 | Kristin.Chasen@McKesson.com McKesson Appoints Tracy Faber to Top HR Role Jorge Figueredo and Kathy McElligott to retire IRVING, T
Read more →-MCK
Jan 31, 2019McKESSON REPORTS FISCAL 2019 THIRD-QUARTER RESULTS Revenues of $56.2 billion for the third quarter, up 5% year over year. Third-quarter GAAP earnings per diluted share from continuing operations of $2.41. Third-quarter A
McKESSON REPORTS FISCAL 2019 THIRD-QUARTER RESULTS SAN FRANCISCO, January 31, 2019 McKesson Corporation (NYSE:MCK) today reported that revenues for the third quarter ended December 31, 2018, were $56.2 billion, up 5% compared to $53.6 billion a year ago, and also up 5% on a cons
Read more →-MCK
Nov 28, 2018EXECUTION VERSION McKESSON CORPORATION 3.650% Notes due 2020 4.750% Notes due 2029 Underwriting Agreement
EXECUTION VERSION McKESSON CORPORATION 3.650% Notes due 2020 4.750% Notes due 2029 Underwriting Agreement November 28, 2018 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 United States of America BNP Paribas Securities Corp. 787 Seventh Ave
Read more →-MCK
Nov 1, 2018JOHN HAMMERGREN ANNOUNCES RETIREMENT; BRIAN TYLER TO BECOME McKESSON S
JOHN HAMMERGREN ANNOUNCES RETIREMENT; BRIAN TYLER TO BECOME McKESSON S CEO AND EDWARD MUELLER TO CHAIR BOARD SAN FRANCISCO November 1, 2018 McKesson Corporation (NYSE:MCK) today announced that John H. Hammergren, chairman and chief executive officer (CEO), has decided to retire
Read more →-MCK
Oct 25, 2018McKESSON REPORTS FISCAL 2019 SECOND-QUARTER RESULTS Revenues of $53.1 billion for the second quarter, up 2% year over year. Second-quarter GAAP earnings per diluted share from continuing operations of $2.51. Second-quart
McKESSON REPORTS FISCAL 2019 SECOND-QUARTER RESULTS SAN FRANCISCO, October 25, 2018 McKesson Corporation (NYSE:MCK) today reported that revenues for the second quarter ended September 30, 2018, were $53.1 billion, up 2% compared to $52.1 billion a year ago, and also up 2% on a c
Read more →-MCK
Jul 26, 2018McKESSON REPORTS FISCAL 2019 FIRST-QUARTER RESULTS Revenues of $52.6 billion for the first quarter, up 3% year over year. First-quarter GAAP loss per diluted share from continuing operations of $(0.69). First-quarter Adj
McKESSON REPORTS FISCAL 2019 FIRST-QUARTER RESULTS SAN FRANCISCO, July 26, 2018 McKesson Corporation (NYSE:MCK) today reported that revenues for the first quarter ended June 30, 2018, were $52.6 billion, up 3% compared to $51.1 billion a year ago. On a constant currency basis, r
Read more →-MCK
Jun 28, 2018MCKESSON REAFFIRMS FISCAL 2019
MCKESSON REAFFIRMS FISCAL 2019 GUIDANCE AND PROVIDES PRELIMINARY GUIDANCE FOR THE FIRST QUARTER SAN FRANCISCO June 28, 2018 McKesson Corporation (NYSE:MCK) today reaffirmed its Adjusted Earnings per diluted share guidance of $13.00 to $13.80 for the fiscal year ending March 31,
Read more →-MCK
May 24, 2018SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION We are furnishing to investors supplemental historical financial information by new reportable segment for our quarterly and annual results of fiscal 2018 as well as
SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION We are furnishing to investors supplemental historical financial information by new reportable segment for our quarterly and annual results of fiscal 2018 as well as annual results for fiscal 2017 and 2016. We believe the pre
Read more →-MCK
May 24, 2018McKESSON REPORTS FISCAL 2018 FOURTH-QUARTER AND FULL-YEAR RESULTS Revenues of $51.6 billion for the fourth quarter and $208.4 billion for the full year. Fourth-quarter GAAP loss per diluted share from continuing operatio
McKESSON REPORTS FISCAL 2018 FOURTH-QUARTER AND FULL-YEAR RESULTS SAN FRANCISCO, May 24, 2018 McKesson Corporation (NYSE:MCK) today reported that revenues for the fourth quarter ended March 31, 2018, were $51.6 billion, up 6% compared to $48.7 billion a year ago. On a constant
Read more →-MCK
Apr 30, 2018McKesson Corporation Craig Mercer, 415-983-8391 (Investors and Financial Media) Craig.Mercer@McKesson.com or Kristin Hunter Chasen, 415-983-8974 (General and Business Media) Kristin.Chasen@McKesson.com McKesson B
McKesson Corporation Craig Mercer, 415-983-8391 (Investors and Financial Media) Craig.Mercer@McKesson.com Kristin Hunter Chasen, 415-983-8974 (General and Business Media) Kristin.Chasen@McKesson.com McKesson Board of Directors Elects Brad Lerman as New Independent Director
Read more →-MCK
Apr 25, 2018McKESSON LAUNCHES MULTI-YEAR STRATEGIC GROWTH INITIATIVE; REAFFIRMS FISCAL 2018 OUTLOOK AND PROVIDES PRELIMINARY FISCAL 2019 OUTLOOK McKesson announces a multi-year growth initiative, focused on creating innovative new s
McKESSON LAUNCHES MULTI-YEAR STRATEGIC GROWTH INITIATIVE; REAFFIRMS FISCAL 2018 OUTLOOK AND PROVIDES PRELIMINARY FISCAL 2019 OUTLOOK SAN FRANCISCO, April 25, 2018 McKesson Corporation (NYSE:MCK) today announced a multi-year strategic growth initiative, focused on creating inno
Read more →-MCK
Feb 7, 2018McKESSON CORPORATION Floating Rate Notes due 2020 1.625% Notes due 2026 Underwriting Agreement
McKESSON CORPORATION Floating Rate Notes due 2020 1.625% Notes due 2026 Underwriting Agreement February 7, 2018 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 United States of America J.P. Morgan Securities plc Merrill Lynch International 2 King Edwar
Read more →-MCK
Feb 1, 2018McKESSON REPORTS FISCAL 2018 THIRD-QUARTER RESULTS Revenues of $53.6 billion for the third quarter, up 7% year-over-year. Third-quarter GAAP earnings per diluted share from continuing operations of $4.32, up 51% year-ove
McKESSON REPORTS FISCAL 2018 THIRD-QUARTER RESULTS SAN FRANCISCO, February 1, 2018 McKesson Corporation (NYSE:MCK) today reported that revenues for the third quarter ended December 31, 2017, were $53.6 billion, up 7% compared to $50.1 billion a year ago. On the basis of U.S. gen
Read more →-MCK
Dec 18, 2017McKESSON ANNOUNCES DEPARTURE OF JAMES BEER, EVP AND CFO; APPOINTS INTERNAL SUCCESSOR, BRITT VITALONE; REAFFIRMS FISCAL 2018
McKESSON ANNOUNCES DEPARTURE OF JAMES BEER, EVP AND CFO; APPOINTS INTERNAL SUCCESSOR, BRITT VITALONE; REAFFIRMS FISCAL 2018 OUTLOOK SAN FRANCISCO, December 18, 2017 McKesson Corporation (NYSE:MCK) today announced James Beer, executive vice president and chief financial officer
Read more →-MCK
Oct 26, 2017McKESSON REPORTS FISCAL 2018 SECOND-QUARTER RESULTS Revenues of $52.1 billion for the second quarter, up 4% year-over-year. Second-quarter GAAP earnings per diluted share from continuing operations of $0.01, down 99% yea
McKESSON REPORTS FISCAL 2018 SECOND-QUARTER RESULTS SAN FRANCISCO, October 26, 2017 McKesson Corporation (NYSE:MCK) today reported that revenues for the second quarter ended September 30, 2017, were $52.1 billion, up 4% compared to $50.0 billion a year ago. On the basis of U.S.
Read more →-MCK
Jul 27, 2017McKESSON REPORTS FISCAL 2018 FIRST-QUARTER RESULTS Revenues of $51.1 billion for the first quarter, up 3% year-over-year. First-quarter GAAP earnings per diluted share from continuing operations of $1.44, down 50% year-o
McKESSON REPORTS FISCAL 2018 FIRST-QUARTER RESULTS SAN FRANCISCO, July 27, 2017 McKesson Corporation (NYSE:MCK) today reported that revenues for the first quarter ended June 30, 2017 were $51.1 billion, up 3% compared to $49.7 billion a year ago. On the basis of U.S. generally a
Read more →-MCK
Jun 28, 2017McKESSON REAFFIRMS FISCAL 2018
McKESSON REAFFIRMS FISCAL 2018 GUIDANCE SAN FRANCISCO, June 28, 2017 McKesson Corporation (NYSE:MCK) today reaffirmed its earnings guidance for the fiscal year ending March 31, 2018 and the underlying key assumptions provided in its press release on May 18, 2017. McKesson is ho
Read more →-MCK
May 18, 2017In the first quarter of fiscal 2018, McKesson Corporation ( McKesson, the Company, or we and other similar pronouns) updated its definition of Adjusted Earnings (Non-GAAP) to provide better clarity on its operating perfo
In the first quarter of fiscal 2018, McKesson Corporation ( McKesson, the Company, or we and other similar pronouns) updated its definition of Adjusted Earnings (Non-GAAP) to provide better clarity on its operating performance as a result of recent strategic changes and underlyin
Read more →-MCK
May 18, 2017McKESSON REPORTS FISCAL 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS Revenues of $48.7 billion for the fourth quarter and $198.5 billion for the full year, up 4% year-over-year. Fourth-quarter GAAP earnings per diluted shar
McKESSON REPORTS FISCAL 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS SAN FRANCISCO, May 18, 2017 McKesson Corporation (NYSE:MCK) today reported that revenues for the fourth quarter ended March 31, 2017, were $48.7 billion, up 4% compared to $46.7 billion a year ago. On a constant c
Read more →-MCK
Mar 2, 2017McKESSON AND CHANGE HEALTHCARE COMPLETE THE CREATION OF NEW HEALTHCARE INFORMATION TECHNOLOGY COMPANY New Company Is Named Change Healthcare Company Is Positioned To Meet Mission Critical Needs In Healthcare SAN FRANCISC
McKESSON AND CHANGE HEALTHCARE COMPLETE THE CREATION OF NEW HEALTHCARE INFORMATION TECHNOLOGY COMPANY New Company Is Named Change Healthcare Company Is Positioned To Meet Mission Critical Needs In Healthcare SAN FRANCISCO & NASHVILLE, March 2, 2017 McKesson Corporation (NYSE:
Read more →-MCK
Feb 13, 2017EXECUTION VERSION McKESSON CORPORATION 0.625% Notes due 2021 1.500% Notes due 2025 Underwriting Agreement
EXECUTION VERSION McKESSON CORPORATION 0.625% Notes due 2021 1.500% Notes due 2025 Underwriting Agreement February 13, 2017 Barclays Bank PLC 5 The North Colonnade Deutsche Bank AG, London Branch Winchester House 1 Great Winchester Street London EC2N 2DB MUFG Securiti
Read more →-MCK
Jan 25, 2017McKESSON REPORTS FISCAL 2017 THIRD-QUARTER RESULTS Revenues of $50.1 billion for the third quarter, up 5% year-over-year. Third-quarter GAAP earnings per diluted share from continuing operations of $2.86, up 6% year-over
McKESSON REPORTS FISCAL 2017 THIRD-QUARTER RESULTS SAN FRANCISCO, January 25, 2017 McKesson Corporation (NYSE:MCK) today reported that revenues for the third quarter ended December 31, 2016, were $50.1 billion, up 5% compared to $47.9 billion a year ago. On the basis of U.S. gen
Read more →-MCK
Dec 21, 2016McKESSON AND CHANGE HEALTHCARE ANNOUNCE TERMINATION OF HART-SCOTT-RODINO ACT WAITING PERIOD FOR THE CREATION OF A NEW HEALTHCARE INFORMATION TECHNOLOGY COMPANY SAN FRANCISCO & NASHVILLE
McKESSON AND CHANGE HEALTHCARE ANNOUNCE TERMINATION OF HART-SCOTT-RODINO ACT WAITING PERIOD FOR THE CREATION OF A NEW HEALTHCARE INFORMATION TECHNOLOGY COMPANY SAN FRANCISCO & NASHVILLE, December 21, 2016 McKesson Corporation (NYSE:MCK), a leading global healthcare services and
Read more →-MCK
Oct 27, 2016McKESSON REPORTS FISCAL 2017 SECOND-QUARTER RESULTS AND REVISED FISCAL 2017 OUTLOOK Revenues of $50.0 billion for the second quarter, up 2% year-over-year. Second-quarter GAAP earnings per diluted share from continuing o
McKESSON REPORTS FISCAL 2017 SECOND-QUARTER RESULTS AND REVISED FISCAL 2017 OUTLOOK SAN FRANCISCO, October 27, 2016 McKesson Corporation (NYSE:MCK) today reported that revenues for the second quarter ended September 30, 2016, were $50.0 billion, up 2% compared to $48.8 billion
Read more →-MCK
Jul 27, 2016McKESSON REPORTS FISCAL 2017 FIRST-QUARTER RESULTS Revenues of $49.7 billion for the first quarter, up 5% year-over-year. First-quarter GAAP earnings per diluted share from continuing operations of $2.88, up 15% year-ove
McKESSON REPORTS FISCAL 2017 FIRST-QUARTER RESULTS SAN FRANCISCO, July 27, 2016 McKesson Corporation (NYSE:MCK) today reported that revenues for the first quarter ended June 30, 2016 were $49.7 billion, up 5% compared to $47.5 billion a year ago. On the basis of U.S. generally a
Read more →-MCK
Jul 5, 2016McKESSON AND CHANGE HEALTHCARE TO FORM NEW HEALTHCARE INFORMATION TECHNOLOGY COMPANY New entity to combine majority of McKesson Technology Solutions and Change Healthcare into separate company positioned to address the h
McKESSON AND CHANGE HEALTHCARE TO FORM NEW HEALTHCARE INFORMATION TECHNOLOGY COMPANY SAN FRANCISCO & NASHVILLE, June 28, 2016 McKesson Corporation (NYSE:MCK), a leading global healthcare services and information technology company, and Change Healthcare Holdings, Inc., a leadin
Read more →-MCK
Jun 29, 2016MCKESSON UPDATES FISCAL 2017
MCKESSON UPDATES FISCAL 2017 GUIDANCE SAN FRANCISCO, June 29, 2016 McKesson Corporation (NYSE:MCK) today announced that for the fiscal year ending March 31, 2017, the company has updated its previous guidance range of $13.30 to $13.80 per diluted share to a new range of $13.43 t
Read more →-MCK
May 4, 2016McKESSON REPORTS FISCAL 2016 FOURTH-QUARTER AND FULL-YEAR RESULTS Revenues of $46.7 billion for the fourth quarter and $190.9 billion for the full year, up 7% year-over-year. Fourth-quarter GAAP earnings per diluted shar
McKESSON REPORTS FISCAL 2016 FOURTH-QUARTER AND FULL-YEAR RESULTS SAN FRANCISCO, May 4, 2016 McKesson Corporation (NYSE:MCK) today reported that revenues for the fourth quarter ended March 31, 2016 were $46.7 billion, up 4% compared to $44.9 billion a year ago. On a constant cu
Read more →-MCK
Jan 27, 2016McKESSON REPORTS FISCAL 2016 THIRD-QUARTER RESULTS Revenues of $47.9 billion for the third quarter, up 3%. Third-quarter GAAP earnings per diluted share from continuing operations of $2.71, up 33%. Third-quarter Adjusted
McKESSON REPORTS FISCAL 2016 THIRD-QUARTER RESULTS SAN FRANCISCO, January 27, 2016 McKesson Corporation (NYSE:MCK) today reported that revenues for the third quarter ended December 31, 2015 were $47.9 billion, up 3% compared to $46.5 billion a year ago. On a constant currency ba
Read more →-MCK
Jan 11, 2016McKESSON ANNOUNCES FISCAL 2016 EARNINGS UPDATE AND PRELIMINARY FISCAL 2017 OUTLOOK Revised Fiscal 2016 Outlook: Adjusted Earnings per diluted share of $12.60 to $12.90. Preliminary Fiscal 2017 Adjusted Earnings per dilut
McKESSON ANNOUNCES FISCAL 2016 EARNINGS UPDATE AND PRELIMINARY FISCAL 2017 OUTLOOK SAN FRANCISCO, January 11, 2016 McKesson Corporation (NYSE:MCK) today announced an update to its outlook for Adjusted Earnings per diluted share for the fiscal year ending March 31, 2016, from the
Read more →-MCK
Oct 29, 2015McKESSON REPORTS FISCAL 2016 SECOND-QUARTER RESULTS Revenues of $48.8 billion for the second quarter, up 10%. Second-quarter GAAP earnings per diluted share from continuing operations of $2.65, up 29%. Second-quarter Adj
McKESSON REPORTS FISCAL 2016 SECOND-QUARTER RESULTS SAN FRANCISCO, October 29, 2015 McKesson Corporation (NYSE:MCK) today reported that revenues for the second quarter ended September 30, 2015 were $48.8 billion, up 10% compared to $44.2 billion a year ago. On a constant currenc
Read more →Competitive Position
How MCK ranks across every disease it competes inCompetitive Position is a premium feature
See how MCK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial